Cantor Fitzgerald Has Positive View of RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Tuesday, March 11th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($3.65) for the year, up from their prior forecast of ($5.29). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.14. The business had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Other analysts also recently issued research reports about the stock. HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Bank of America decreased their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Finally, Morgan Stanley decreased their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $9.76 on Thursday. The company has a market capitalization of $1.03 billion, a PE ratio of -3.10 and a beta of 1.36. The company has a 50 day simple moving average of $12.47 and a two-hundred day simple moving average of $15.01. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences has a fifty-two week low of $9.01 and a fifty-two week high of $19.18.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $10.06 per share, with a total value of $201,200.00. Following the transaction, the director now owns 28,400 shares in the company, valued at $285,704. This trade represents a 238.10 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. 12.30% of the stock is currently owned by insiders.

Institutional Trading of Arcus Biosciences

Several hedge funds have recently bought and sold shares of the business. Woodline Partners LP lifted its stake in Arcus Biosciences by 1.3% during the 4th quarter. Woodline Partners LP now owns 3,523,937 shares of the company’s stock valued at $52,471,000 after acquiring an additional 45,497 shares in the last quarter. Two Sigma Advisers LP lifted its stake in Arcus Biosciences by 35.8% during the 4th quarter. Two Sigma Advisers LP now owns 58,800 shares of the company’s stock valued at $876,000 after acquiring an additional 15,500 shares in the last quarter. Two Sigma Investments LP lifted its stake in Arcus Biosciences by 8.1% during the 4th quarter. Two Sigma Investments LP now owns 146,686 shares of the company’s stock valued at $2,184,000 after acquiring an additional 11,027 shares in the last quarter. Tema Etfs LLC bought a new position in Arcus Biosciences during the 4th quarter valued at $331,000. Finally, ProShare Advisors LLC lifted its stake in Arcus Biosciences by 44.4% during the 4th quarter. ProShare Advisors LLC now owns 16,379 shares of the company’s stock valued at $244,000 after acquiring an additional 5,038 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.